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Abstract 
APEl/Ref-1 (APEl), the mainmalian ortholog of Escherichia coli Xth, and a inultifw1ctional protein possessing 
both DNA repair and trai1scriptional regulatory activities, has a pleiotropic role in controlling cellular response 
to oxidative stress. APEl is the maii1 apurinic/ apyrin1idinic e11donuclease in eukaryotic cells, playii1g a ce11tral 
role in the DNA base excision repair pathway of all DNA lesions (uracil, alkylated and oxidized, ai1d abasic 
sites), including single-strand breaks, and has also cotranscriptional activity by modulating genes expression 
directly regulated by either ubiquitous (i.e., AP-1, Egr-1, NF-KB, p53, and HIF) and tissue specific (i.e., PEBP-2, 
Pax-5 and -8, and TTF-1) transcriptio11 factors. In additio11, it controls the intracellular redox state by inhibiting 
the reactive oxygen species (ROS) production. At present, ii1formation is still inadequate regarding the molec-
ular mechmis1ns responsible for the coordii1ated control of its several activities. Both expression md/ or sub-
cellular localization are altered in several metabolic md proliferative disorders such as in tumors md aging. 
Here, we have attempted to coalesce the most relevai1t information concemii1g APEl's different functio11s in 
order to shed new light md to focus current and future studies to fully understand this unique molecule that 
is acquiring n1ore and more interest and trai1slational relevance in the field of molecular medicii1e. Antioxid. 
Redox Signal. 11, 601-619. 
Introduction: An Overall View on APE1. General 
Considerations on APE1 Biological and Molecular 
Functions. Involvement of APE1 in Controlling Pro-
Apoptotic and Pro-Survival Transcription Factors. Is 
This a Biological Paradox? 
CELLULAR RESPONSE TO OXJDA TJVE STRESS is a highly regu-lated and complex biological process (42). APEl/Ref-1 
(also called HAPl or APEX, and here referred to APEl), the 
mammalian ortholog of Escherichia coli Xth (exonuclease 111), 
is a vital protein that acts as an essential master regulator of 
this response, highly contributing to the maintenance of the 
genome stability. After cloning by h-vo independent groups 
in 1991 (21, 114) as a DNA repair enzyme first and as a re-
d ox protein the following year (144), APEl has been de-
scribed, in -300 articles, as playing a role in several biolog-
ica I contexts. APEl is a dual function protein involved both 
in the base excision repair (BER) pathvvays of DNA lesions, 
acting as the major apurinic/ apyrimidinic endonuclease, 
and in eukaryotic transcriptional regulation of gene expres-
sion. This effect is obtained as a redox co-activator of differ-
ent transcription factors such as the early growth response 
protein-1 (Egr-1), nuclear fac tor-KB (NF-KB), p53, hypoxia in-
ducible factor-la (HIP-la), cAMP response element binding 
protein (CREB), activator protein-1 (AP-1), and paired box-
containing proteins (Pax) in different cell systems (126). 
These h-vo biological activities are located in h-vo function-
ally distinct domains. The N-terminus, containing the nu-
clear localization signal (NLS) region, is principally devoted 
to the redox activi ty, through Cys65, while the C-terminus 
exerts the enzymatic activity on the abasic sites of DNA (146) 
(Fig. lA). Homology with Exolll star ts from residue 62. A 
Blast homology search clearly displays the peculiar distri-
bution of the primary structure conservation of APEl 
1Department of Biomedical Sciences and Teclu1ologies, University of Udine, Udine, Italy. 
2Centro Sn1di Fegato, AREA Science Park, and Deparanent of Life Sciences, Univel'Sity of Trieste, Trieste, Italy. 
3 Department of Ped iatrics, Hennan B Wells Center for Ped iatric Research, and the Deparbnents of Biocl1emistry and Ntolecular Biol-
ogy, and Phannacology and Toxicology, Indiana Universi ty School of Medicine, Indianapolis, Indiana. 
601 
602 
A 
Redox 
NLS 
1 20 127 161 
. 
. 
. 
. . 
. . 
. . 
. . 
• . 
• • • c 0 CKI (34, 148) E56 $100 $123 
-ca PKC >- E56 Tl>l 
... (34,62, 148) 0 
J:: 
Q, CKll (34, 148) T19 
"' 0 J:: GSK3 (34,148) 0.. 
Redox 
C65 C93 (61, 109, 132, 141 , 146) 
Acetylation (7,30) K6/7 
Proteolysis (15,29,52, 150) K31 
S-nitrosation (110) C93 
B 
endonucfease 
~ APE~ APE1 
0 No· 5' -Cleavage o -: . - T- C A-T- C- -T-C '.' A-T-C-1 I I I I - I I I I I 
- A- C-T-T- A-C- - A-C-T- T- A- C -
3' -Phosphodiesterase 
Mismatched Repair 
Nucleotide Removal 
APEi APE1 
o · No. 
- T- C- - T- C- - T- C .-. A- T- C-
1 I I I - I I . I I I 
<f) -A-C-T-T-A-C- -A-C-T-T-A-C-
<tt'lj 
'>.'\<,o APE1 APE1 
0 o· No· . . . . 0 ... . 
-T-C > A- T-C- - T- C ·> A-T-C-
1 I 11 1 - 11 1 1 1 -
-A-C- T-T-A-C- -A-C-T-T-A-C-
Long Patch Repair 
Gpc - polymerase, 
PCIA, RFC 
$ 123 
$123 
13-polymerase 
XRCC1 
Ligase 
APE1 '~ 
Jl ,,,. ' - T-C - T-C-
- I I I I I 
-A-C- T-T-A-C-
PCIA. FB 11, Ligase 
TELL ET AL. 
DNA Repair 
318 
• • T268 $3
S201 $252 
T233 
S298 
10 
C310 
c 
Transcriplion COOH 
H2N Faclor 
'®__,, 
DBD 
DNA 
COOH 
SH SH 
Target gene expression 
Regulatory region 
FIG. 1. Representations of APEl domains structure and functions. (A) Schematic structure, based on functional studies 
(66, 144) of APEl structure v.rith critical residues. Schematic diagram of putative or experimental determined post-transla-
tional modifications of APEl/Ref-1. CKI, casein kinase I; CKTI, casein kinase IT; GSK3, glycogen synthase kinase 3; NLS, 
nuclear localization signal; PKC, protein kinase C. (B) APE1 fun ctions in base excision repair. FEN1, flap endonuclease 1; 
MPG, methylpurine DNA glycosylase; Oggl, 8-oxoguanine DNA glycosylase, PCNA, proliferating cell nuclear antigen; 
RFC, replication factor C; XRCCl, X-ray cross-species complimenting 1. (C) Theoretical molecular model of the redox func-
tion of APEl as a transcriptional coactivator of several transcription factors. Thioredoxin (Trx) is responsible for complet-
ing the redox cycle by which APEl reduced form is restored. DBD, DNA binding domain. 
(http://www.expasy.ch/ cgi-bin/blast.pl, accession number: 
P27695). While the C-terminal part of the protein is highly con-
served during phylogeny, the N-terminus is not. Besides in the 
man1malian proteins, in which the N-terminus is highly con-
served (> 90o/o), this region is almost always absent in other or-
ganisms, with the exception of Zebra.fish, Drosophilil, Xenopus, 
and Dictyosteliun1, v.rhere homology is < 40°/o, suggesting that 
it may be a recent acquisition of evolution. 
The redox function of APEl is found only in mammals 
and not in other vertebrates, as demonstrated by the lack of 
redox function of the Zebrafish APEl (zAPEl). The acquisi-
tion of the redox function in APEl proteins is d iscussed in 
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a recent publication (39). The two major functions of APEl, 
redox and repair, are completely independent in their ac-
tions, as shown by the observation that a mutation of the Cys 
at position 65 (C65) abolishes the redox function but does 
not affect the repair function (86), whereas mutation of a va-
riety of amino acids required for DNA repair activity, such 
as Histidine 309 (H309) and others (87, Vascotto et al., un-
published observations), do not affect the redox function. 
While the DNA repair active site of APEl has been clearly 
delineated (44, 90), the redox domain is much less defined. 
The only Cys residue required for full redox function is C65, 
which is buried \·Vithin the APEl protein (44, 90), as recently 
confirmed by Georgiadis who mutated in the zAPEl a Thr 
(T58) to a Cys located at the same position of the Cys in the 
mammalian APEl, resulting in the acquisition of redox ac-
tivity of the mutated protein (39). 
The vital role of APEl seems to be due to its fundamen-
tal activity in the base excision repair (BER) pathvvay of DNA 
lesions (35). However, the biological relevance in eukaryotic 
transcriptional regulation of gene expression as a redox co-
activator of different transcription has yet to be fully eluci-
dated (126). 
Another interesting function is associated to its abili ty to 
indirectly bind to the negative calcium response elements 
(nCaRE) of some promoters (i.e., parathyroid hormone (PTH) 
and APEl promoters) acting as a transcriptional repressor. 
In particular, binding to nCaRE-B, in the PTH gene promoter, 
requires Ku70 (Ku86) as an additional factor in the complex 
(17), while binding to nCaRE-B2 in the APEl promoter in-
volves hnRNPL in teraction (77). This activity seems to be 
regula ted by acetylation of APEl through the CBP /p300 
HAT action (7). A more recent finding has identified APE1's 
role in mediating production of single-strand DNA (ssDNA) 
breaks in gene promoters during repair of targeted base ox-
idation lesions caused by oxygen radicals generated during 
physiologic signaling (10, 153, 154). Thus, defects in the 
APEl-mediated step in BER pathway could be Jinked to al-
tered gene expression besides altering transcription factor 
state. This is discussed later in this review. 
APEl subcellular distribution, in different mammalian cell 
types, is mainly nuclear and is critical in controlling cellular 
proliferative rate (35, 57, 67). Interestingly, the expression of 
APEl is strictly connected to d ifferent tumorigenic processes 
(126). The necessity of APEl for cellular survival and its fre-
quent overexpression in tumor cells strongly suggest a fun-
damental role of this protein in preventing cell death and in 
controlling cellular proliferation. However, APEl abilities to 
activate transcription factors, such as p53 and Egr-1 (14, 30, 
38, 54, 64, 107, 117), mainly involved in controlling cell-cy-
cle arrest and apoptotic programs, leave open the debate con-
cerning the mechanisms responsible for controlling the dif-
ferent functions in several contexts. APEl protein is also 
localized within mitochondria in different cell types but, at 
present, the role in this organelle has not been completely 
elucidated (15, 88, 122), as well as the molecular mechanism 
regulating its mitochondrial localization (15). 
The fact that APEl is essential for cell viability was origi-
nally demonstrated by genetic studies. Knockout of APEl in 
mice causes postimplantation embryonic lethality on days 
ES to E9 (85, 147), and attempts to isolate stable APEl-knock-
out cell lines were totally unsuccessful. For these reasons, a 
detailed comprehension of molecular targets of APEl func-
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tions has been very difficult. ln the last 3 years, conditional 
knockout and knockdovvn strategies (35, 67, Vascotto et al., 
unpublished observations) confirmed the crucial role of this 
protein for cellular existence and allo\.\red the establishment 
of cell models to better investigate and characterize the ma-
jor functions of APEl. However, complete knowledge of mo-
lecular effectors regulated by APEl in determining its bio-
logical essentiality is still scanty. The necessity of APEl for 
mammalian cells seems to be mainly due to its DNA repair 
activity in BER pathway. Interestingly, attempts to restore 
the DNA repair activity in cells not expressing APEl, by us-
ing the yeast homologous Apnl (35) which Jacks the redox-
transcriptional activation domain, or an APEl mutant lack-
ing the acetylation sites but not the DNA repair activity (67), 
or "''ith the redox-defective mutant C65S (Vascotto et al., un-
published observations) did not completely restore the loss 
of cell viability. Moreover, by specifically blocking the APEl 
redox but not DNA activi ty with an APEl -specific redox in-
hibitor, E3330, it has been shown that the cytokine-n1ediated 
hemangioblast development in vitro was significan tly im-
paired (155). Collectively, these data demonstrate that the ex-
act knowledge of the precise molecular mechanisms for 
APEl's vital role in mammalian cells is still inadequate. They 
do, however, indicate that the repair function is crucial for 
survival and the redox function for cell growth (Vascotto et 
al., unpublished observations). 
DNA Repair Activity of APE1 
It is already 1~rel l established that a plethora of base lesions 
are induced in mammalian cell genomes by different phys-
ical and chemical agents, among which reactive oxygen 
species (i.e., 0 2·, I-120 2 and 'OH, collectively named ROS) 
play a dominant role. These lesions, if not adequately re-
paired, are at the basis of a variety of diseases (including can-
cer) and of aging. 
The BER is the most used pathway to cope '~rith the sin-
gle base lesion. The BER pathway is also involved in repair-
ing the DNA single-strand breaks (SSB) induced by free rad-
ical agents. One of the key enzymes of the BER pathway in 
mammals is APEl. The basic reactions of the BER path\~ray 
have been extensively reviewed (26, 58, 81, 88, 126). They re-
quire the coordinated activity of a number of enzymes in-
cluding: (a) a DNA glycosylase capable of excising a specific 
modified base; (b) an AP endonuclease, such as APEl, which 
cleaves the S' phosphodiester bond, generating 3'0H and 
S'dRP termini; (c) an exonuclease activity (,8-polymerase, 
FEN, APEl); (d) a DNA polymerase (.B-polymerase, XRCCl 
or o Is-polymerase with PCNA); and, finally (e) a ligation ac-
tivity (DNA ligases l and Ill, XRCCl), (Fig. lB).The three 
ways by which APEl produces the 3'0H terminus for prim-
ing and the types of evolutionarily conserved amino acids 
necessary for these functions have been already reviewed 
(26, 58 and other articles in this issue of ARS). 
All the steps of the BER pathway are finely orchestrated, 
both from the thermodynamic and the kinetic point of view, 
to provide an accurate repair of the damaged base and to 
avoid the generation of intermedia te products that are toxic 
for the cell (58). This implies the coordinated interaction of 
the various players in the BER process and, when necessary, 
their further interaction with the DNA replication machin-
ery, as demonstrated by the co-immunoprecipitation of the 
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BER repair proteins with cyclin A and DNA replication pro-
teins (103). In this context, it is noteworthy that RP A pro-
teins are able to suppress the APEl endonuclease activity in 
ssDNA of a replicative fork but not in a transcription bub-
ble or in dsDNA (27) and that Cockayne syndrome B pro-
tein potentiates the APEl activity on ful ly paired AP-DNA 
but much more on bubble AP-DNA, suggesting a role for 
this protein in the transcription-repair pa thway (143). 
Of particular interest in the definition of new functions 
and targets of APEl is the finding that, after UV A irradia-
tion, APEl co-localizes with Oggl in the nuclear speckles, 
organelles associated to transcription and RNA processing. 
This localization is abolished in the presence of antioxidants 
(12), s uggesting that ROS are the driving force of this local-
ization. Another interesting APEl function, connected to its 
capacity to bind to SSB, is that of inhibiting the same bind-
ing by PARPl, vvitl1 consequent inactivation of the poly-
ADP-ribosylation and p revention of necrosis (121). 
A good exan1ple of how APEl m.ay use its dual nature to 
produce a cut in the DNA strand and to activate other pro-
teins is that of the VEGF gene which contains a hypoxic re-
sponse element (HRE) target of HIP-la. Oxygen deprivation 
induces formation of an abasic site in the response element 
follov.red by 1-IIF-la binding. The data suggest that the aba-
sic site is the target of APEl activity with consequent in-
creased flexibility of DNA which causes HlF-1 binding (10) 
and transcriptional activation of the VEGF gene (46, 153). 
Very recently, a role for APEl (and for APE2) has been 
suggested also in the antibody class switch recombination, 
where the abasic site generated by uracil DNA glycosylase, 
following cytosine deamination, is converted in a single-
stranded break by a standard AP-endonuclease procedure 
(51). Additionally, the recently found inhibitory crosstalk be-
tween the oncogene protein Bcl2 and the DNA repair activ-
ity of APEl (152), suggests a novel mechanism which may 
promote genetic instability and tumorigenesis. 
Redox Regulation of Transcription Factors Activities 
The intracellular redox status reflects the balance beh~reen 
the activity of antioxidant enzymatic and nonenzymatic cell 
systems (including GSH/GSSG, superoxide dismutase, cata-
lase, peroxidases, glutathione peroxidases, etc.) and the 
amount of ROS produced: (a) as byproducts of respiration; 
(b) as a consequence of external noxious agents such as ion-
izing radiation; (c) as 'second messengers' (23, 42); and (d) 
during pathological states in activated neutrophils (93). Of 
notice is the observation that variations in the redox state 
may result in alterations in gene expression profile asset. The 
molecular mechanism at the basis of this regulation is ex-
erted through the modulation of transcription fa ctors (TFs) 
activity. In particular, the redox sta tus of reactive Cys 
residues, located within the DNA-binding domain of some 
TFs, may control the transcriptional activity of the TFs itself. 
APEl has been identified as a protein capable of nuclear re-
dox activity, inducing the DNA binding activity of several 
transcription factors, such as AP-1 (144), NF-KB (95), Myb 
(145), PEBP2 (1), 1-ILF (25), NF-Y (94), Egr-1 (14, 64), 1-UF-la 
(63), ATF/CREB family (145), p53 (38, 54, 117), and Pax pro-
teins (13, 128, 129). In each case, this effect was accomplished 
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by maintaining the cysteine residues of the TFs in the re-
duced state (Fig. lC), through a redox cycle in v.rhich Trx 
would restore the reduced form of APEl (61, 109, 132, 141). 
By using 'in vitro' assays, it has been shown that Cys65 is the 
redox-active site of the protein (39, 139). Since Cys65 appears 
buried in the 3-D model structure of the p rotein (44, 90), the 
redox regulation may implicate the occurrence of unfolding 
or conformational change of APEJ to allow interaction with 
redox-sensitive TFs. However, Jayaraman et al . suggested 
that the stimulatory role played by APEl on p53 activity may 
also occur in a redox-independent way (70). This was sub-
sequently corroborated by Ordway et al. (101) who provided 
the first in vivo evidences that the Cys65 residue of APEl is 
unexpectedly not essential for redox regulation of AP-1 DNA 
binding and, thus, challenging the previous hypotheses. 
However, the presence of compensato1y mechanisms occur-
ring in transgenic mice cannot be excluded, and recent pub-
lication by Georgiadis et al. has confirmed the original find -
ing of Cys65 being required for APEl redox function (39). 
Regulation of APE1 at the Gene Expression Level, at 
the Subcellular Localization Level, and Role of 
Identified Posttranslational Modifications 
APEl functional activation is a consequence of different 
stimuli that may generate both physiological and toxic ox-
idative stress conditions or increase the intracellular cAMP 
levels leading to different outcomes (Fig. 2). 
The regulatory functions of the different APEl activities can 
be fine-tuned and implemented via three different mecha-
nisms: (a) increase in APEl's level after transcriptional activa-
tion (107, 108, 111, 126); (b) relocalization of APEl from the cy-
toplasm to the nucleus (126); and (c) modulation of APEl's 
post-translational modifications (PTM), such as acetylation and 
phosphorylation. As recently demonstrated, in addition to re-
dox regulation, acetylation appears to have a fine-tuning role 
in affecting APEl's different activities (7, 30, 67). 
Both in vivo and in vitro studies demonstrated that differ-
ent oxidative or toxic agents and I or intracellular p roduced 
ROS effi ciently and rapidly (within minutes to hours, de-
pending on the specifi c ROS-generating stimuli) p romote a 
transient increase in APEl protein levels, which is inhibited 
by cyclohexirnide (111, 129). Different transcription factors, 
including Sp-1 (36), Egr-1 (107), STAT3 (53), CREB (48), and 
Jun/ ATF4 (37) are involved in the inducible expression of 
APEl. APEl itself may inhibit its own expression through 
the binding to nCa-RE sequences within the APEl d istal pro-
moter, thus constituting an autoregulatory functional loop 
(68). In addition, APEl expression is linked in a positive au-
toregulatory loop with Egr-1 (107), and in a negative in-
hibitory loop with p53 (151). Interestingly, p rotein upregu-
lation is always associated with an increase in both redox 
and AP endonuclease activity, followed by an increase in cell 
resistance toward oxidative stress and DNA damaging 
agents (49, 87, 88, 111, 126), strengthening the conclusion that 
an upregulation of APEl protein levels has profound bio-
logical consequences. 
The activation of APEl is also obtained by a process in-
dependent from de nova synthesis and involves cytoplasm 
to nucleus translocation after exposure of cells to oxidative 
PLEIOTROPIC PROTEIN APE1/REF-1 605 
Stimulus or pathological conditions 
UV and -y-radiation 
Propos ed biological role 
Detoxification of xenobiotics 
' Hypoxia , ' 
' 
' 
' 
' 
' 
' 
' lschemia/Reperfusion, ', 
' ' 
• 
' 
Protection against 
hypoxic stress 
' ' ' 
FIG. 2. Schematic representa-
tion of some of the s timuli known 
to activate APEl/Ref-1 expression 
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comes. Thus, APEl is a centra 1 
actor in the adaptive cellular re-
sponse to oxidative stress. 
Hypoxic-ischemic insult ••••• ···-.,:··, ~ 
H. pylori infection . . ••••• ~ ---.. Neuronal protection ~ against oxidative stress .. .. .. • trr.. .... ........ t Nucleus ROS. . .. ·· •.. .._ 
.... .... 
------ -- --- ->-
Atherosclerotic - . -- . -- -- -· · · · ·.,.... APE1 /Ref-1 ------~~ Proliferation 
plaque . . ... . . ----~ 
TSH - · · · · · · · ••• ••.. :~ t Expression =------~ IL-8 production 
• • • CD40 triggering • · ••• • • • ;tf 
P2Y triggering • • • •• • • • • • .-' ).. 
. ' 
DNA repair 
. ' 
. ' 
. ' Cysteamine-induced • • : 
' 
• 
• 
• 
• 
• 
• duodenal ulceration : 
• 
• 
• 
• 
Redox regulation of 
TFs activity ' 
' 
' 
' 
tin Intracellular Ca++ ! 
stress conditions (111, 126, 127) or upon physiologic in-
crease in intracell ular ROS production (108). Nuclear lo-
calization of APEl is controlled by the first 20 amino acids 
at the N-terminal sequence, as determined by Jackson et al. 
(69) and nuclear import is controlled through a bipartite 
NLS comprising residues 1-7 and 8-13 with the involve-
ment of an importin system. In fact, the first 20 residues 
directly bind to karyopherin al and a2. Data obtained by 
treatment of cells with the nuclear export inhibitor lepto-
mycin B suggested the presence of a nuclear export signal 
(NES) that may reside in a Leu-rich region (L291, L292, 
L295 residues, which are exposed in the 3-D structure) (69). 
Recently, it has been shown that the region comprising 
amino acids 64- 80 contains a NES (110). Thus, both n u-
clear import and export may control subcellu lar distribu-
tion of APEl. Tn addition, the interaction 1-vith specific n u-
clear proteins could be a means to maintain APEl within 
the nucleus. This hypothesis, recently proposed by Jung et 
al. based on their data showing that nuclear localization of 
APEl was dependent on GADD45a nuclear protein ex-
pression (71), deserves further experimental support. 
·During the last few years, several lines of evidence have 
been accumulating, demonstrating that functional triggering 
of membrane-bound receptors (such as those for TSH, 
CD40L, ATP, IL-2, etc.) can lead to APEl functional activa-
tion through intracellular generation of sublethal doses of 
ROS (126). Noteworthy is the observation that APEl is also 
directly responsible for the control of the intracellular ROS 
levels through its inhibitory effect on Rael (2, 52, 102, Vas-
cotto et al., unpublished observations), the regulatory sub-
unit of a membrane nonphagocytic NADPI-I oxidase system. 
This enzyme, composed of multiple membrane-associated 
(l\tlox and p22Ph0x) and cytosolic components (p67P110x, p47P110x, 
and Rael), catalyzes the transformation of the molecular oxy-
gen to the superoxide anion by transferring an electron from 
the substrates NADH or NADPH (3). Since we have recently 
demonstrated that NADPH-mediated ROS production in-
• Pb• Development of apoptosis 
Asbestos 
duced by P2Y triggering \.Vas able to promote APEl func-
tiona 1 activation (108), we propose the existence of an au-
toregulatory loop between these two systems. This mecha-
nism may be of therapeutic relevance for endothelial, 
fibroblastic, and smooth muscle cells, and should be ana-
lyzed in diseases of the vascular system where an overacti-
vation of the NADPH oxidase system is involved (19), as 
well as in the angiogenesis process (133), \vhere an additional 
autoregulatory loop between APEl and VEGF may be in-
ferred (10, 153). This observation could be therapeutically 
relevant in the treatment of tumor progression and cancer 
metastasis. 
Based on the above-mentioned considerations, APEl 
seems to act as an intracellular signaling tool involved both 
in modulating the cellular response to acute and chronic ox-
idative stress conditions, and also in controlling the en-
dogenous ROS levels during the physiological generation of 
ROS as intracellular signaling molecules. Since the cell sys-
tem must be able to discriminate between different ROS-gen-
erating stimuli, APEl behaves as an integrating signaling 
molecule. 
APEl is an abundant protein (-104-105 copies/cell) 
within eukaryotic cells and with a relatively long half-life 
[-8 h (Vascotto et al., unpublished observations)]. Therefore, 
the fine-tuning of the multiple functions of this pleiotropic 
protein may reside in the impact tha t PTMs have on the func-
tion of APEl and on the modulation of the APEl-interac-
tome under different conditions. Whereas for the forn1er hy-
pothesis some experimental evidences have been obtained 
(acetylation of K6/K7 residues (7, 30)], very little informa-
tion is no\v available on the protein interacting partners of 
APEl. Pioneering in silica studies discovered that several dif-
ferent phosphorylation sites were scattered throughout the 
molecule. These potential phosphorylation sites included 
consensus sequences for casein kinase I and II (CKI and 
CKII), for protein kinase C (PKC), and for GSK3 (Fig. lA) 
(34, 148). Initial in vivo studies confirmed a role for PKC in 
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phosphorylating APEl in response to PMA or to alkylating 
agents (i.e., MMS) leading to AP-1 activation (62). 1-Iowever, 
these studies have not been repeated nor followed up. There-
fore, the role of phosphorylation on APEl is still not clear. 
APEl is a site for redox regulation by the dithiol-reducing 
enzyme Trx (61, 109, 132, 141), through Cys35 and Cys32 in 
the catalytic center of Trx, and involving the Cys65 redox 
sensitive site of APEl (139, 141, 146). The Trx-1nediated re-
dox regulation of APEl is required for the functional acti-
vation of p53 (132) and AP-1 (61). Though the biological rel-
evance of Cys65 residue seems determined, it is not currently 
kno\<vn whether this Cys residue undergoes PTM in vivo. 
Qu et al. (110) demonstrated that two (Cys93 and Cys310) 
of the seven Cys residues of APEl can undergo S-nitrosation 
in response to nitric oxide stimulation, leading to nucleus to 
cytoplasm relocalization of the protein in a CRMl-indepen-
dent process, possibly as a consequence of demasking a pu-
tative nuclear export signal (aa 64- 80). S-ni trosation n1ay 
therefore constitute a specific molecular switch to strictly 
control the intracellular distribution of APEl between nu-
cleus and cytoplasm, and provides a new working hypoth-
esis for the cytoplasmic accumulation of APEl observed in 
more aggressive tumors (126). Unfortunately, no detail is 
available about the functional implications of S-nitrosation 
on the different biological functions of APEl. Accordingly, 
since both NO and APEl are associated \.\Tith tumorigenesis 
and neurodegenerative diseases, future work is needed to 
address whether nitrosative stress leads to genomic insta-
bility, and may be the target for designing new therapeutic 
strategies. 
An interesting post-translational processing that has been 
recently described is proteolysis occurring at residue Lys31. 
This PT regulation of APEl protein is responsible for en-
hanced cell death mediated by granzyme A (GzmA) (29) and 
granzyme K (GzmK) (52). APEl is associated \~Tith the endo-
plasmic reticulum in a macromolecular complex of 270-420 
kDa containing evolutionarily conserved proteins called SET, 
pp32, and rlMG2. GzmA cleaves APEl after Lys31, giving rise 
to a protein form called N~33APE1, and alters its ability to be 
actively accumulated within nuclei of cells (15, 69, and our 
unpublished observations) and to interact \~Tith XRCCl (136). 
Ho\.\1ever, some authors claimed tha t truncated APEl may 
loose its AP-endonuclease activity (29) and acquire a nonspe-
cific DNAse function (150). This peculiar processing is not lim-
ited to immune cells but may constitute a general molecular 
device for redirecting APEl to mitochondria (125), as sug-
gested by Chattopadhyay et al. (15) and Mitra et al. (88), in 
spite of the intriguing finding of a proteolysis occurring at the 
level of Asn33 rather than Lys31. Again, if the removal of the 
terminal 31- 33 amino acids is responsible for APEl to move 
to the mitochondria to function in mitochondrial BER as an 
AP endonuclease, it is hard to understand this truncated pro-
tein having nonspecific DNAse activity (150) unless it is ve1y 
cell-type specific. Accordingly, previous work by many in-
vestigators has never observed a nonspecific nuclease activ-
ity with the cleavage of the first 61 amino acids (66) and ad-
ditional data clearly showed that the truncated APEl protein 
has an unaltered AP-endonuclease activity (15, and our un-
published observations), at least in vitro. 
While it is known that nuclear accumulation of APEl trig-
gers the activation of several transcription factors, the func-
tional role of acetylation is barely understood. Acetylation 
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of both histones and regulatory proteins is commonly cat-
alyzed by the histone acetyltransferase (HAT) p300/CBP, 
and can be reversed by histone deacetylases (HDACs), which 
in turn control the acetylation level of transcription factors 
or co-activators (50, 74). Bhakat et al. have reported that the 
balance between the acetyltransferase activi ty of p300/CBP 
and the deacetylase activity of HDACl maintains APEl's 
acetyla tion at Lys residues 6 and 7 (K6, K7) in response to 
Ca2 + levels, thus controlling expression of target genes (7). 
More recently, we found that exposure of 1-IeLa cells to I-120 2 
and to histone deacetylase inhibitors increases acetylation of 
APEl at residues Lys6/Lys7, leading to Egr-1-mediated in-
duction of the tumor suppressor PTEN gene expression (30). 
Our data open ne\.\T perspectives in the comprehension of the 
many functions exerted by APEl in controlling cell response 
to oxidative stress and underline the double-face nature of 
APEl which plays a role in both pro-survival and in cell cy-
cle arrest mechanisms. Interestingly, despi te the very low ho-
mology degree in the N-terminal region (<40o/o), K6 or 
K6/K7 are much more conserved, thus reinforcing their pri-
mary role during phylogenesis. 
Altogether, these observations have raised the possibility 
that subtle PTMs provide a means for channeling the multi-
functional APEl to different activities and interactions and 
thus could act as a regulatory switch in performing differ-
ent functions. APEl subcellular localization is quite variable. 
Most cell types exhibit only nuclear, others display only cy-
toplasmic, while others show both nuclear and cytoplasmic 
localization (126). Such a complex distribution pattern sug-
gests that localization is not random but, on the contrary, is 
controlled by a strictly regulated process. Though of funda -
mental interest for a full comprehension of the role of APEl 
in different pathological conditions, the clear understanding 
of the biological relevance of APEl subcellular compart-
mentalization still remains elusive. Whereas ,.ve can rather 
easily figure out the role for nuclear localization of APEl 
based on its main DNA repair and co-transcriptional activ-
ity, a convincing explanation for the extranuclear roles of 
APEl is still evanescent. Cytoplasmic localization of APEl, 
such as that reported for fibroblasts, spermatocytes, thyro-
cytes, lymphocytes, hepatocytes, and hippocampal cells (20, 
22, 24, 72, 73, 112, 126, 129, 142), is associated with high meta-
bolic or proliferative rates and may be rela ted to a cell cy-
cle-dependen t expression (36). Possible explanatory hy-
potheses for cytoplasmic expression of APEl may come from 
the mitochondrial role of the protein, as described above. A 
further functional explanation comes from its association 
with endoplasmic reticulum membranes, as evidenced by ul-
trastructural (125) and biochemical (28, 29, 47) analysis. It 
has been suggested that APEl redox activity in the cytoplasm 
may be required to maintain newly synthesized transcrip-
tion factors in a reduced state during their translocation to 
the nucleus (24). Therefore, future work is required to shed 
more light on the extranuclear role(s) of APEl, starting from 
the explanation o f its cytoplasmic function. 
Molecular Basis for the Vital Role of APE1 in 
Mammalian Cells: New Perspectives 
To understand the vital role of APEl in mammalian cells, 
we recently combined gene expression array and proteomics 
analysis to identify the genes directly or indirectly regulated 
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by APEl. By generating an inducible knockdown cell model, 
in which endogenous APEl expression could be inhibited by 
siRNA teclmology (Vascotto et al., unpublished observa-
tions), we built up the molecular nehvorks in which APEl 
is involved (see Fig. 3A, B, and C for models network). APEl 
silencing induces apoptosis through mitochondrial path\.vay 
and a strong inhibitory effect on cell growth. There is evi-
dence of p53 activation and perturbation of the glucocorti-
coid receptor signaling pathway that could explain an in-
duction of apoptosis. Glucocorticoid receptor NR3Cl 
(GCR-alpha) itself is do\~rnregulated, upon APEl silencing, 
whereas p53 is not. Instead, a large number of p53 controlled 
transcription factors are differentially expressed in our APEl 
silencing experiment, further supporting an important role 
of APEl in modulating p53 functions (38, 54, 117) (Fig. 38 
and C). Differentially expressed genes in our model strongly 
indicate a significant perturbation of the glucocorticoid re-
ceptor signaling pathvvay. Proteins of the HSP70 complex 
(i.e., HSPAlA, HSPAlB, and HSPA8) are significantly up-
regula ted as a consequence of APEl silencing, and it is 
known that HSP70 is required for the assembly of the glu-
cocorticoid receptor-HSP90 complex (92). Moreover, other 
key components and targets of glucocorticoid receptor sig-
naling pathway were also on our gene list (Egr-1, C/EBP-
beta, c-Myc, SUM0-4, 14-3-3 proteins, and tubulin proteins). 
One of the genes that emerged from our analysis and is 
involved in the control of cell growth processes, as well as 
in the antioxidant response, is Egr-1. This transcription fac-
tor resulted as a good candidate target of APEl, since its ex-
pression was significantly reduced in APEl knocked-down 
cells both basally and upon serum treatment after starvation 
(Fig. 4A). We therefore investiga ted the functional effect of 
APEl silencing in controlling the expression of one of the 
most well-kno\·vn Egr-1 target genes, the tumor suppressor 
PTEN, which is induced upon UV- and oxidative stress-cel-
lular damage (5, 137). An impairment of Egr-1 expression 
upon APEl silencing affected the inducible expression of 
PTEN gene with a transcriptional mechanism, confirming 
the dual nature of APEl itself (Fig. 4B and C). Thus, the lack 
of APEl impairs the adaptive cellular response to damaging 
agents. These findings further enlighten the double nature 
of APEl to be involved in both the processes of cell growth 
and in gro1~1th arrest upon cellular damage. Interestingly, 
this kind of dual role nature in transcriptional regulation and 
DNA repair for proteins is consistently present in the five 
major DNA repair pathways, that is, homologous recombi-
national repair (HRR), nonhomologous end joining (NHEJ), 
nucleotide excision repair (NER), BER and mismatch repair 
(MMR), as in the cases of BRCAl, ATM, and p53 itself (for 
revie\.v, refer to Ref. 6). The existence and the correct regu-
lation of a mechanism shifting cells from DNA repair to 
apoptosis is central to avoid progression to cancer, prevent-
ing clonal expansion of cells in which unrepaired damage 
would lead to mutation and to carcinogenesis. In this regard, 
it is interesting to note that a number of DNA repair genes 
(i.e., GADD45, BRCAl) were do1.vnregulated as a conse-
quence of APEl silencing, suggesting the existence of a cross-
regula tion of the expression beh.veen individual partners of 
different pathways and underlining the central role of APEl 
in DNA repair processes with a different function besides 
the well-known AP-endonuclease activity. This hypothesis 
will require further investigation. 
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The interesting finding that, besides its activity as a re-
dox coactivator for Egr-1 transcriptional activity (64, 107), 
APEl is also able to regulate Egr-1 expression levels rein-
forces the previously suggested hypothesis (107) of the ex-
istence of a functional loop between APEl and Egr-1 in rec-
iprocally modulating each other. This finding strengthens 
the biological complexity typica l of this multifunctional 
protein and could well be a n1olecular tool by which APEl 
may regulate the expression of DNA repair genes such as 
GADD45 (130). 
Egr-1 activates the transcription of genes in response to a 
variety of mitogenic and nonrnitogenic stimuli, including 
growth factors and hypoxia (75) and it is able to form redox-
modulated transcriptional complexes with the AP-1 as \~rell 
as vvith APEl and Trx (76). Accordingly, in line with the data 
obtained in our cell model, the role of Egr-1 seems to be piv-
otal. The central effect of APEl on Egr-1 biological functions 
is also reinforced by the concomitant downregulation of ad-
di tional Egr-1 target genes such as C/EBP/3, VEGF and c-
Myc (Vascotto et al., unpublished observations; 135). Based 
on these findings the net\ovorking model depicted in Fig. 4D 
was assembled. 
Future Perspectives in Elucidating the Pleiotropic 
Function of APE1 in Mammalian Cells at the Molecular 
Level. Looking at the Roles of the Mitochondrial and 
the Subnuclear Distribution of APE1. Could the 
N-Terminal Unconserved Domain Make the Difference? 
As mentioned above, removal of APEJ NLS through pro-
teolysis controls the amount of APEl present within the nu-
clear compartment and would constitute an elegant tool to 
control APEl alternative functions in noncanonical subcel-
lular compartments, as mitochondria. Unfortunately, in non-
immune cells, neither the identity of the specific protease re-
sponsible for this cleavage nor the mitochondrial localization 
signal (MTS) have been determined yet. The relatively high 
molecular weight of APEl is not fully compatible with a pas-
sive mechanism of translocation through the outer mem-
brane of mitochondria, and therefore it may require the pres-
ence of a specific regulatory transport mechanism. Whereas 
a large majority of proteins synthesized in the cytoplasm lo-
calize in to mitochondri.a by means of an N-terminal MTS, a 
significant fraction of mitochondrial proteins lack this recog-
nition signal. In the case of APEl, it has been suggested that 
the MTS may reside in the C-terminal 69 amino residues of 
the protein (110). Mitochondrial localization of APEl may be 
associated to a potential role in DNA repair of oxidized bases 
in the mitochondrial genome (15, 88, 126). However, since it 
is not clear whether, in vivo, NC.33APE1 maintains its DNA 
repair activity (29) or, as previously suggested, may acquire 
an aspecific endonuclease activity for dsDNA in vitro (150), 
at present it is impossible to derive any definite conclusion. 
Moreover, since generation of truncated NC.33APE1 form is 
associated with the occurrence of an apoptotic phenotype 
(52; Vascotto et al., unpublished observations), it cannot be 
excluded that this APEl form may be causatively involved 
in the cytotoxic effect driving pro-apoptotic triggering di-
rectly from mitochondria. Preliminary data obtained in our 
laboratory in cells expressing a noncleavable mutant APEl 
protein (i.e., 31- 34A mutant) seem to support this hypothe-
sis. Should this be confirmed, strategies to modulate the pro-
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FIG. 4. Functional inactivation of Egr-1 transcrip tional activity on PTEN target gene. HDACs inhibitors-induced PTEN 
upregulation requires APEl expression. (A) Inducible expression of Egr-1 by 1 h serum treatment after o/n starvation is 
significantly reduced in APEl-silenced cells. Endogenous APEl silencing was obtained by inducible RNAi strategy (30). Ex-
pression of Egr-1 and APEl proteins '~'as evaluated by Western blot analysis on 10 µ,g of nuclear extracts as previously de-
scribed (30). (B) Induction of endogenous PTEN expression by HDACs inhibitors is inhibited in HeLa cells in which Egr-1 
is diminished upon constitutive stable APE1 knock-down. To evaluate the endogenous PTEN levels upon HDACs inhibi-
tors treatment, control and knocked-down HeLa cells " 'ere treated with TSA for 30 h and further collected and lysed to ob-
tain total extracts that were subsequently used for Western blot analysis. Ten µ,g of extracts were separated onto a lOo/o SDS-
p AGE, blotted onto nitrocellulose membranes, and assayed for the presence of APEl protein by using the monoclonal 
anti-APEl antibody, for the presence of PTEN protein by using the monoclonal anti-PTEN antibody and for the presence 
of Egr-1 protein by using a speci fic polyclonal antibody. Actin was also measured, as loading control. Values represent the 
relative amount of PTEN with respect to control untreated cells, after normalization for actin content. The 1nean value of 
l\~ro independent experiments is reported. (C) Induction of PTEN promoter activity by HDACs inhibitors is prevented in 
constitutive stable APEl knocked-down HeLa cells in which Egr-1 is significantly diminished. APEl silencing " 'as obtained 
as described in legend to (A). After 10 days of doxycycline treatment, HeLa cells were transfected with plasmid containing 
the PTEN promoter-Luc sequence and then treated with TSA for 30 h. Twenty-four hours after treatment, cells were har-
vested, and luciferase and ,B-galactosidase activities were measured. Bars indicate the mean value+ SD of three indepen-
dent experiments. (*p < 0.05 by Student's t-test). (D) Model network involving APEl-Egr 1 functional interaction. This model 
neh~rork is accessible at this site: https://portal.genego.com/pub/network/n-839812191.html. (For interpretation of the ref-
erences to color in this figure legend, the reader is referred to the " 'eb version of this article at www.liebertonline.com/ars). 
FIG. 3. Different model networks for APEl -mediated signaling as derived by gene expression and proteomic data. Di-
rect interaction network for genes dysregulated upon APEl knock-down, involved in redox control, transcription regula-
tors and chaperones (A) and (B) and in p53-signaling (C). Colors of the symbols indicate inhibition (blue) and activa tion 
(red). Here, the name APEX is used to refer to A PEl . This model neh-vork is accessible at this site: https: // 
portal.genego.com/pub/network/n-860173808.html. (For interpretation of the references to color in this figure legend, the 
reader is referred to the vveb version of this article at www.liebertonline.com/ars). 
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teolytic removal of the APEl N-terminus will constitute a 
possible good candidate target for future drug development. 
On the other side, it is not completely clear whether trunca-
tion of APEl N-terminus may affect APEl redox activity (29, 
52), leaving open the debate on the biological meaning of the 
process. Since the N-terminal region of the protein seems to 
be a result of phylogenetic evolution, it is intriguing that this 
part of the protein could account for the difference in mod-
ulating the various functions of APEl. 
In addition to the canonical 37 kDa APEl protein, and the 
truncated Nt.33APE1 form, in some circumstances the ap-
pearance of a lovver mobility band of - SO kDa has been de-
tected (our unpublished data). This form vvould account for 
a PTM that introduces a substantial modification to the wild-
type protein. A recently identified PTM, typically occurring 
on Lys residues of several nucleoproteins, is sumoylation (40, 
56). The addition of a small ubiquitin-like modifier (SUMO) 
molecule to the target p rotein accounts for an increase of - 12 
kDa of the apparent molecular n1ass of the target protein it-
self. Many SUMO-modified proteins function in regulation 
of transcription, chromatin structure, maintenance of the ge-
nome stability, and signal transduction. Upon sumoylation, 
interactions that are dependent on other post-translational 
modifications or on unmodified lysine are lost. Sumoylation 
also promotes novel interactions, in some cases associated 
with a conformational change in the target protein. The ef-
fects of PTM by SUMO to compete for target lysines enhance 
or inhibit interactions '~'ith other proteins (or other binding 
partners, such as DNA) or induce conformational changes. 
These effects are not mutually exclusive, but might not all 
occur on the same substrate. Thus, we investigated the pos-
sibility tha t APEl may undergo sumoylation. APE1 protein 
contains 29 Lys residues, 15 of them lie in the N-te1minal do-
main, and 14 residues lie in the C-terminal domain of the 
protein. Protein sequence analysis using three different soft-
wares for prediction of sumoylation sites (SUMO Plot, SUMO 
sp, and SUMO PSFS) revealed several "low probability" pu-
tative sumoylation sites and a "high probability" putative 
sumoylation site, \-vhich contains a canonical sumoylation 1/J-
K-X-D IE motif (Fig. SA and B). Putative sumoylation sites 
do not distribute homogenously along the whole sequence, 
but concentrate at the N-terminal domain, which is not pres-
en t in functionally related proteins from other organisms and 
is required for the redox activity of APEl. Co-localization ex-
periments on cells transfected with GFP-SUM0-1 clearly 
demonstrated that endogenous APEl can be modified by 
wild-type SUM0-1 but not by a deletion mutant (i.e., 
t.6SUM0-1), which looses its ability to modify target pro-
teins (Fig. SC). Jn vitro sumoylation experiments also clearly 
demonstrated that APEl may undergo sumoylation (un-
published data). Our inability to identify the Lys residue tar-
get of sumoylation, by mutagenizing the putative sumoyla-
tion sites identified during in silica analysis (unpublished 
data), may suggest that multiple Lys residues could be the 
simultaneous target of this PTM. Additional work, which is 
difficult as sumoylated APEl represents a very tiny fraction 
in comparison to the nonsumoylated protein, is required to 
understand the role of sumoyla ti on in controlling APEl func-
tions. 
In summary, all of these studies have confirmed the dual 
role nature of APEl, as a prototypical example of an appar-
ent biological paradox. While a number of reports clearly 
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demonstrated the antiapoptotic roles as well as the positive 
effect on cell proliferation (for a review, see Ref. 126, and 35, 
67, 88), other data underlined its potential role in controlling 
proapoptotic functions through pS3-mediated activation of 
p21 (38, 54, 117), leading to the arrest of cell cycle by in-
hibiting cyclin-dependent kinase function (11 ), and cyclin G, 
having pro-apoptotic activity (97). However, it is becoming 
increasingly evident that the antiapoptotic roles of APEl are 
ascribable to its DNA repair functions (35) rather than to its 
activities as a transcriptional co-activator. Thus, it is tempt-
ing to speculate that the latter function-activation of tran-
scription factors (i.e., p53 and Egr-1) ensuring efficient cell-
cycle arrest- may act in concert with the previous (repair of 
DNA damage) to protect cells from accumulation of oxida-
tive damage (Fig. 6) and be a later evolutionarily acquired 
function since only mammals and not just vertebrates ap-
pear to have the redox signaling function (39). This may have 
been an advantageous addition to APE1's interactions and 
functions that benefi ted mammalian cells, given the poten-
tially toxic nature of their environment. This may have sub-
sequently led to additional signaling and regulatory inter-
actions and func tions. Obviously, for a proper modulation 
of these two interconnected functions, a fine-tuned regula-
tion of APEl activities is required. Thus, a better under-
standing of the processes controlling APEl subcellular dis-
tribution, of the post-translational modifications occurring 
on the protein itself, of the mechanisms controlling protein 
half-life, and of the different interacting partners recruited 
as a function of cellular response, is required to fully address 
this paradoxica I issue. 
Clinical Perspectives: Altered Expression/Distribution 
of APE1 and Human Pathology 
Accumulating evidence has demonstrated that the het-
erogeneity of APEl expression pattern is linked to different 
pathological conditions ranging from metabolic to differen-
tiative disorders, including cancer and neurodegenerative 
diseases. Different kinds of human tumors were character-
ized by alterations in subcellular distribution of APEl with 
respect to nontumoral tissue (73; for review, see 126). Gen-
erally, APEl localization is eminently nuclear, while in 
several carcinomas a nuclear, cytoplasmic, and nuclear I 
cytoplasmic staining was observed (126). This peculiar dis-
tribution correlates well with the aggressiveness and prog-
nosis of the tumor as nuclear localization was always asso-
ciated with a better prognostic feature together with a higher 
degree of cellular differentiation, low angiogenesis, and neg-
ative lymph node status. As in hepatocellular carcinoma 
(HCC), a cytoplasmic localization of APEl was associated 
with a significant lo,-ver degree of differentiation and with a 
shorter survival time, the localization of APEl in liver biopsy 
is of prognostic value (22). Noteworthy, alteration in sub-
cellular distribution of APEl is not functionally related to the 
ability of cancerous tissue to repair a basic sites, suggesting 
that DNA repair by BER may not be affected (8, 113, 115). 
Therefore, it appears that the extranuclear roles of APEl are 
responsible for its association with cancer. 
\.Vhether the alterations of APEl subcellular localization 
are causally responsible or only associated with tumor 
progression is not clear at present. However, our recent 
findings in HCC, in which a chronic cellular oxidative 
PLEIOTROPIC PROTEIN APE1/REF-1 
A 
NLS 
1 20 
Potential Lys 3 
sumoylation sites 
B 
c 
27 32 
6 
Redox 
127 161 
63 125 
78 85 CONSENSUS: 1jJKxD/E 
- APE1/Ref-1 -
SUMO Plot" 
score 
K 3 + 0,43 
K 6 + 0.50 
K 27 -
-
K 32 + 0,48 
K 63 - -
K 78 + 0,3 1 
K 85 + 0,93 
K 125 + 0.33 
"GramalikoH K el al. (45a). 
bXuo 01 al. (147a). 
'liu el al. (79a). 
SUMO spb 
score 
- 1, 19 
- 2.00 
+ 7,00 
- 2,01 
+ 14,00 
+ 4,00 
+ 2,95 
-
0.25 
SUMO PSFSo 
score 
- -
- -
- -
+ 0.11 
- -
- -
+ 1,20 
- -
DNA Repair 
Motifs with high probability 
Motifs with low probability 
611 
318 
FlG. 5. (A) APE1 protein sequence bears several putative sun1oylation si tes, as fron1 in silica analysis. APE1 protein con-
tains 29 Lysine residues, 15 of them lie in the N-terminal domain of the protein. Protein sequence analysis using three dif-
ferent softwares for prediction of sumoylation sites (SUMOPlot, SUMO sp, and SUMO PSFS) revealed several "lovv prob-
ability" putative sumoylation sites and a "high probability" putative sumoylation site, vvhich contains a canonical 
sumoylation ~1-K-X-D/E motif. Putative sumoylation sites do not distribute homogenously along whole sequence, but con-
centrate at N-terminal domain, vvhich is not present in functionally rela ted proteins from other organisms and is required 
for the redox activity of APEl. (B) Of the 29 Lys residues, 8 of them are identified as potential surnoylation sites vvi th the 
three different softwares. Lys85represents a classical consensus sequence, recognized by all progr ams. Lys78 is recognized 
as low-probability consensus sites by two different programs, while five Lys residues (K3, K6, K27, K63, and Kl25) are rec-
ognized as potential sumoylation sites by only one program. Interestingly, all potential sumoylation sites reside within the 
Redox transactivation domain. (C) APEl colocalizes with SUM0-1, but not with ~6 SUM0-1, into nuclear subdomains, pre-
sumably nuclear bodies. HeLa cells were transfected with either pGFPSUM0-1 or pGFP~6SUMO-l, as a negative control. 
The inactive ~6SUM0-1 is a deletionmutant lacking the 6 C-terminal aminocid residues, including double glycines being 
the site for the isopeptidic bond with the target protein, whichcannot sumoylate target proteins located in the nuclear bod-
ies. Thus, this mutant relocalizes within nucleus and cytoplasm in a diffuse way. APEl staining vvas analyzed using a mono-
clonal anti-APEl antibody. Primary antibody and GFPSUM0-1 staining were revealed by incubation with Alexa Fluor 546 
conjugated secondary antibody or by intrinsic green fluorescence of GFP, respectively. Merging of the two colors results in 
a yellow signal, co1Tesponding to co-localized proteins. (For interpretation of the references to color in this figure legend, 
the reader is referred to the web version of this article at www.liebertonline.com/ars). 
612 TELL ET AL. 
Oxidative stress 
! 
APE1/Ref-1 
! Acetylation, phosphorylation, redox, 
Sumoylation, proteolysis Enhanced expression 
PT modifications 
Subcellular localization 
Nucleus, mitochondria ER 
DNA repair 
Cell survival 
Egr- 1, p53, NF-KB, 
Transcriptional activation AP-1, Pax, HIF-1o., ! ATF, GREB, HLF 
Gene expression {p21, eye/in G, pTEN 
i 
Cell-cycle arrest, Apoptosis, 
Antioxidant response, cell growth 
FIG. 6. Model of APEl multifunctional roles in coordinating cell response to oxidative stress. APEl has dual functions 
in cellular response tooxidative stress by acting as an AP-endonuclease in DNA repair and as a transcriptional regulator of 
various transcription factors leading to cell-cycle arrest or to cell survival. APEl's post-translational modifications and reg-
ulation of its intracellular trafficking may be critical in in vivo fine-tuning of its activities. 
stress conditions (91) in a milieu of inflammation (106) 
plays a central role in tumor progression implying func-
tional activa tion of p ro-survival transcription factors such 
as NF-KB and STAT3 (43, 84), supports the latter conclu-
sion. To definitely address this point, it is mandatory that 
the interactome network of APEl as \.Vell as the role of 
PTM in controlling the cytoplasmic localization of the pro-
tein must be unveiled. An interesting working hypothesis 
for a role of APEl in the inflammatory process comes from 
recent works on APEl-mediated IL-8 production in Heli-
cobacter pylori infections (96). These authors demonstrated 
that APEl is required for H. pylori infection-mediated in-
duction of IL-8 production by gastric cells through the in-
volvement of NF-KB and AP-1 transcription factors (96). 
Thus, APEJ seems to play also a leading role in the pro-
duction of inflammatory cytokines. Fu ture work will be 
needed to extend these observations and to open new ap-
plicative perspectives in molecular medicine. 
Other than in proliferative disorders mentioned above, 
APEl deregulation has also been demonstrated in other 
pathologies, in particular degenerative disorders. Neu-
rodegenerative diseases, such as Alzheimer's disease, 
Parkinson's disease, and amyotrophic lateral sclerosis 
(ALS), are characterized by a condition of chronic oxida-
tive stress that primarily contributes to the pathogenesis 
through apoptosis of neuronal ce.lls (33). APEl is highly 
expressed in selected regions of the central nervous sys-
tem (99, 100, 142). A reduction in APEl expression, fol -
lowed by an increase in the apoptotic rate, occurs in the 
hippocampus after a hypoxic-ischemic injury (41), in the 
cortex after compression injury (79), and in the spinal cord 
after ischemia (116). The hippocampus of patients with 
Alzheimer shows an increased expression of APEl levels 
in senile plaques and plaque-like structures (123). Our re-
cent unpublished data demonstrated an increased nuclear 
expression of APEl in neuronal and glial cells of the cere-
bral cortex in both familial and sporadic Alzheimer (Mar-
con et al., unpublished data). These findings, together with 
the observation of an increased DNA repair mechanism in 
Alzheimer {18), may be associated with the cellular adap-
tive response to the oxidative stress condition typical of 
Alzheimer, and may be involved in the pathogenesis of the 
disease. Despite the abundance of APEl in neurons and 
the correlations between alterations in APEl levels and 
various neuropathologies, few studies have addressed the 
role of APEl in preventing neurotoxicity. Recent data dem-
onstrate that APEl protects primary cultures of hip-
pocampal and sensory neurons from oxidative damage in-
duced by H20 2 (134). However, despite its fundamental 
importance for future therapeutic development, the p re-
cise mechanism of the protective effect is still poorly un-
ders tood. 
Translational, Clinical Applications of APE1 Redox 
Inhibition for Cancer or Other Areas 
As discussed in the previous sections, APEl has two pri-
mary and major activities: DNA BER and redox signaling of 
downstream transcription factor targets. While previous 
studies have de1nonstrated that altering APEl levels leads to 
blockage of cell growth and increased cancer cell sensitivity 
(8, 9, 16, 26, 31, 32, 55, 59, 65, 78, 80- 83, 87, 98, 120, 124, 131, 
138, 140, 149), these studies have either used overexpression 
of APE1, APEl antisense oligonucleotides, or APEl siRNA. 
The dilemma with this approach, \.vhile valid, is that each of 
these procedures changes the total cellular content level of 
APEl and removes all of APEl's functions, not just the re-
pair or redox activities. Because APEl has multiple functions, 
as well as interactions with many other proteins (belonging 
to DNA repair, signaling and to the Egr-1 pathway), the in-
crease or decrease of APEl protein may result in multiple ef-
fects in which the APEl's specific role cannot be easily de-
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picted. Furthermore, recent studies tested the hypothesis that 
APEl is responsible for mediating production of single-
strand DNA (ssDNA) breaks in gene promoters during re-
pair of targeted base oxidation lesions caused by oxygen rad-
icals generated during physiologic signaling (10, 153, 154). 
Production of ssDNA breaks is believed to play a key role 
during transcription by imparting substantial flexibility to 
promoter sequences, enabling them to bend in a manner that 
establishes the chromatin architecture needed for gene ex-
pression. In addition, APEl, besides forming the ssDNA 
break, is also required for high-fidelity repair of the break 
(104, 105, 119). Thus, defects in the APEl-mediated step in 
BER pathway could be linked to altered gene expression be-
sides altering transcription factor state. 
Use of specific small molecule inhibitors, such as one that 
blocks APEl redox, but not repair, will be important to de-
lineate the distinct roles of APEl in various cancers, other 
diseases, and normal cellular functions . Likewise, an APEl 
specific repair inhibitor will help to elucidate that role (4). 
Ultimately, using APE1 redox inhibitors with APE1 specific 
endonuclease repair inhibitors will give a clearer picture of 
the multiple activities of APE1. 
APEl \.Vas 01iginally identified as the primary target of 
E3330 (3-(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-
nonyl-2-propionic acid), a small molecule redox inhibitor 
(155). £3330 was immobilized on beads and APEl was iden-
tified from a nuclear extract of a leukemia cell line as a pro-
tein that specifically bound to E3330. Using surface plasmon 
resonance (SPR), an equilibrium constant (Ko) of 1.6 nM was 
obtained for the binding of E3330 to APEl, suggesting a spe-
cific interaction. E3330 was also shown to block the ability 
of APEl to reduce NF-KB, thus interfering with the redox ac-
tiv ity of APEl (45, 60, 89, 118). The proposed binding site on 
APEl is somewhat puzzling. The amino acid residues 72-80 
form a ridge on the surface of the molecule with no obvious 
cavities or binding pockets that are large enough to bind 
E3330. Currently, we are pursuing studies to delineate the 
binding site or region of £3330 on APEl. 
Our recent data have demonstrated that E3330 blocks the 
redox function of APEl with AP-1 as the downstream target 
in vitro (86). Additionally, using a transactivation assay for 
AP-1 or HIF-la targets in ovarian cancer cells, increasing 
amounts of E3330 Jed to decreased activation of a luciferase 
reporter downstream of AP-1 and HIF-la (86). While E3330 
blocked APEl's redox function, it had no effect on APEl re-
pair endonuclease activi ty nor other members of the BER 
pathway (86). These studies demonstrate the specificity of 
E3330 for APEl's redox, but not for its repair function. This 
is supported by our recently published data in ovarian can-
cer studies in xenografts demonstrating that the knockdov.rn 
of APEl results in the blocking of cell gro,.vth and prolifer-
ation, but not necessarily cell death (31). This is the first time 
that cancer cell killing has been reported using a small mol-
ecule inhibitor of APE1 redox function. 
E3330 \.vas also shown to have single agent inhibition of 
cell growth using a variety of cancer cell lines including, 
ovarian, colon, lung, breast, brain, pancreatic, prostate, and 
multiple myeloma cancers (Kelley et al. unpublished obser-
vations). In stark contrast, we do not see significant growth 
inhibition in our studies with normal cells such as hemato-
poietic embryonic cells (155) or in human CD34 + progeni-
tor cells (Kelley et al. unpublished observations). These data 
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are novel in that they implicate the redox role of APEl in 
cancer, but not "normal", cell survival. 
Recent studies using this APEl redox inhibitor in angio-
genesis model systems have been instructive. Proliferation 
of endothelial cells (EC) is an important index for angiogenic 
ability of EC in vitro. £3330 inhibited retina I vascular endo-
thelial cells (RVEC) growth in a dose-dependent manner (86). 
Additionally, an in vitro angiogenesis assay was also used to 
determine the effect of £3330 on RVEC formation of capil-
lary-like structures on Matrigel. The inhibitory effect of 
E3330 was similar to the proliferation assay \.Vith the com-
plete loss of tube formation at low micromolar concentra-
tions. These results demonstrate that blocking APEl's redox 
function attenuates RVEC proliferation and capillary forma-
tion 'in vitro and these findings implicate the use of an APEl 
redox inhibitor in antiangiogenic translational studies. Fur-
ther mechanistic studies as to how this is occurring are in 
progress, although prelin1inary studies indicate the redox in-
hibitory effect is not necessarily related to cell killing, but to 
a block in cell proliferation or cytostatic effect similar to that 
observed using APEl siRNA in vivo (31). 
In conclusion, APEl is a multifunctional protein with both 
important DNA repair and redox capabilities. However, in 
order to demarcate the various functions of APEl, small mol-
ecule inhibitors of each function will be necessary to ulti-
mately conclude \.vhich function is required in normal and 
cancer cell function. Recent findings with redox inhibition of 
APEl have potential clinical translational significance such 
that a redox inhibitor could be used as a single agent, in com-
bination \·vi th current treatments or as a potential antigrowth, 
cytostatic agent. Furthermore, new APEl redox analogues 
could play a role in antiangiogenic therapies. 
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